Sept. 14, 2009 – Abbott said today the Chinese State Food and Drug Administration (SFDA) has approved the XIENCE ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
Feature | Dave Fornell
Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in ...
September 10, 2009
September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus ...
September 03, 2009
September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread ...
September 02, 2009
September 1, 2009 – Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess ...
September 01, 2009
August 13, 2009 – Abbott today announced the expansion of the company's XIENCE V USA post-approval study designed ...
August 13, 2009
August 11, 2009 – Physicians in the United Kingdom yesterday completed patient implants using the first CE mark ...
August 11, 2009
July 16, 2009 – Boston Scientific Corp. today said its received approval from the FDA to market its TAXUS Liberte ...
July 16, 2009July 14, 2009 – Despite the fact that drug-eluting stent (DES) implantation reduces restenosis and the need for ...
July 14, 2009
June 23, 2009 – Abbott said today it received CE mark (Conformite Europeenne) for its next-generation Xience PRIME ...
June 23, 2009June 18, 2009 – Abbott this week initiated SPIRIT PRIME, a clinical trial to study the performance of the company ...
June 18, 2009June 8, 2009 - The Bypass Angioplasty Revascularization Investigation With Diabetes Trial (BARI-2D) is a useful ...
June 08, 2009
June 1, 2009 - Devax Inc. today said FDA has conditionally approved an investigational device exemption (IDE) for ...
June 01, 2009
May 28, 2009 - Boston Scientific Corp. said yesterday it received FDA clearance to market its TAXUS Liberte Atom ...
May 28, 2009May 26, 2009 – AMG International GmbH last week submitted its second-generation drug-eluting stent (DES), Itrix ...
May 26, 2009© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now